£6M initial fundraising
Successful phase II results in cat allergy
3rd funding round (£15M)
Positive phase II results in house dust mite & ragweed allergies
£60M investment round
Start of phase III in cat allergy
Results from phase II cat allergy study show four-dose treatment maintains improvement 2 years later
Raises £200M in successful IPO on the London Stock Exchange
Raises £275M to fund acquisitions of Aerocrine and Prosonix
Circassia (CIR:LSE) is a specialty biopharmaceutical company focused on allergy and asthma. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany and intends expanding this to further countries. These products are also promoted in a number of other territories by the Company’s international network of partners.
Circassia’s broad-based development pipeline includes a range of treatments for allergy and asthma. Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia’s lead asthma product targets substitution of GSK’s Flixotide® pMDI, and was filed for regulatory approval in H2 2014. The Company anticipates two further product filings by the end of H1 2016, targeting direct substitution of Serevent® pMDI and Seretide® pMDI. Circassia is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.
Circassia was established in 2006. The Company made good clinical progress, and in March 2014 undertook a successful initial public offering on the London Stock Exchange, raising over £200 million. In June 2015, the Company completed a further share offer, raising £275 million to advance its strategy to commercialize its products independently and broaden its portfolio through the acquisitions of Aerocrine and Prosonix.